Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 16/20 | 0.48 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.45 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.45 |
| ▸ | SIRT3 | Q9NTG7 | 2/20 | 0.45 |
| ▸ | FURIN | P09958 | 1/20 | 0.45 |
| ▸ | MC1R | Q01726 | 5/20 | 0.44 |
| ▸ | MC3R | P41968 | 8/20 | 0.44 |
| ▸ | MC5R | P33032 | 5/20 | 0.44 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21392265 | 1.00 | MC4R (0.48) | MC4RSIRT2SIRT1SIRT3FURIN | |
| SCHEMBL12092580 | 1.00 | MC4R (0.48) | MC4RSIRT2SIRT1SIRT3FURIN | |
| SCHEMBL20362997 | 0.94 | MC4R (0.47) | MC4RSIRT2SIRT1SIRT3FURIN | |
| SCHEMBL21392481 | 0.94 | MC4R (0.47) | MC4RSIRT2SIRT1SIRT3FURIN | |
| SCHEMBL12092579 | 0.94 | MC4R (0.47) | MC4RSIRT2SIRT1SIRT3FURIN | |
| SCHEMBL12092735 | 0.93 | MC4R (0.47) | MC4RSIRT2SIRT1SIRT3FURIN | |
| SCHEMBL12092650 | 0.92 | MC4R (0.47) | MC4RSIRT2SIRT1SIRT3FURIN | |
| SCHEMBL12092736 | 0.92 | MC4R (0.48) | MC4RSIRT2SIRT1SIRT3FURIN | |
| SCHEMBL20206361 | 0.92 | MC4R (0.52) | MC4RFURINMC1RMC3RMC5R | |
| SCHEMBL12092629 | 0.92 | MC4R (0.52) | MC4RFURINMC1RMC3RMC5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10711039-B2 | Melanocortin receptor-specific peptide with C-terminal naphthylalanine | PALATIN TECHNOLOGIES, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-20180148478-A1 | Melanocortin Receptor-Specific Peptide with C-Terminal Naphthylalanine | PALATIN TECHNOLOGIES INC (US) | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10711039-B2 | Melanocortin receptor-specific peptide with C-terminal naphthylalanine | MC1R, MC3R, MC4R | MC4R 3/4885SIRT2 3928/4885SIRT1 3176/4885 |
| US-20180148478-A1 | Melanocortin Receptor-Specific Peptide with C-Terminal Naphthylalanine | MC1R, MC3R, MC4R | MC4R 3/4885SIRT2 3928/4885SIRT1 3176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.